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Abstract
Objectives: Prion diseases are dementing illnesses with poorly defined neuro-
psychological features. This is probably because the most common form, spo-
radic Creutzfeldt-Jakob disease, is often rapidly progressive with pervasive
cognitive decline making detailed neuropsychological investigation difficult.
This study, which includes patients with inherited, acquired (iatrogenic and
variant) and sporadic forms of the disease, is the only large-scale neuropsycho-
logical investigation of this patient group ever undertaken and aimed to define
a neuropsychological profile of human prion diseases. Methods: A tailored
short cognitive examination of all of the patients (n = 81), with detailed neuro-
psychological testing in a subset with mild disease (n = 30) and correlation
with demographic, clinical, genetic (PRNP mutation and polymorphic codon
129 genotype), and other variables (MRI brain signal change in cortex, basal
ganglia or thalamus; quantitative research imaging, cerebrospinal fluid 14-3-3
protein). Results: Comparison with healthy controls showed patients to be
impaired on all tasks. Principal components analysis showed a major axis of
fronto-parietal dysfunction that accounted for approximately half of the vari-
ance observed. This correlated strongly with volume reduction in frontal and
parietal gray matter on MRI. Examination of individual patients’ performances
confirmed early impairment on this axis, suggesting characteristic cognitive fea-
tures in mild disease: prominent executive impairment, parietal dysfunction, a
largely expressive dysphasia, with reduced motor speed. Interpretation: Taken
together with typical neurological features, these results complete a profile that
should improve differential diagnosis in a clinical setting. We propose a tailored
neuropsychological battery for early recognition of clinical onset of symptoms
with potential for use in clinical trials involving at-risk individuals.
Introduction
Human prion diseases include those inherited as autosomal
dominant traits, those acquired because of prion-contami-
nated food, medical products or instruments, and sporadic
forms. Although dementia is a core clinical feature, most
studies have focused on the neurological and psychiatric,
rather than the specifically cognitive, signs and symptoms.
Many patients are only diagnosed relatively late in the
disease course, a function both of very rapid progression and
its relative rarity. The question of whether there is any
consistency to the cognitive profile has rarely been addressed.
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Phenotypic heterogeneity is regarded as the norm with
variability in presentation mainly reflecting the relative
timing of cognitive to neurological and psychiatric
features. Variant Creutzfeldt-Jakob disease (vCJD) predomi-
nantly affects a younger age group, with prominent early
psychiatric and sensory symptoms, such as limb pain and
dysesthesia.1 Iatrogenic CJD is generally a cerebellar
syndrome followed by cognitive change at a relatively late
stage of the illness.2,3 There are also differences amongst the
inherited forms. For instance, patients with the P102L muta-
tion typically experience cerebellar ataxia well before cogni-
tive dysfunction emerges4,5 while in 6-OPRI (octapeptide
repeat insertion, an inherited prion disease [IPD] mutation
in PRNP) patients cognitive impairment is a prominent
early sign,6,7 with milder or absent cerebellar signs initially.
While cognitive impairment in prion disease is usually
considered to be generalized, some features have recurred
in previous reports. Executive deficits have been reported
in a number of studies.8–10 A second feature, often
remarked but rarely investigated, is progressive loss of
speech.10–13 Prominent visual symptoms – the “Heidenh-
ain variant” of sporadic CJD (sCJD) – have sometimes
been identified.14,15 Memory impairment has figured
more significantly in some studies than others9,10 but is a
less prominent feature than in other dementing illnesses.
Finally, patients, even with rapidly progressive sCJD,
sometimes present with focal cognitive deficits including
hemispatial neglect,16 or language disturbance.12,17
The view that this is a generalized dementia without
distinctive cognitive features has been challenged in one
study.10 Notwithstanding heterogeneity of presentation in
six patients, common qualitative features were observed
including periods of unresponsiveness, intrusion errors
from both auditory and visual stimuli, perseveration in
the context of preserved self-reflection, and preservation
of awareness of illness. They suggested these features
might be characteristic of the disease as such, reflecting a
fundamental impairment in the activation and regulation
of cortical activity from subcortical structures.18,19
In the current study, comprising near comprehensive
nationwide recruitment of patients with all types of
prion disease20 we had a unique opportunity to docu-
ment for the first time the cognitive profile of a large
cohort of prion disease patients including the refinement
of an appropriate battery of tests. We analyzed perfor-
mance on cognitive tests in comparison with matched
controls, grouped by brain region, ranked by commonly
used cognitive and functionally orientated rating scales,
by statistical techniques used to reduce complex data
sets, and by correlation with demographic and clinical
variables, investigations and molecular factors known to
be determinants of phenotypic heterogeneity. The oppor-
tunity to characterize such a profile offers the possibility
of improved operational criteria for diagnosis of the dis-
ease.
Methods
Two cognitive batteries were used: a specially devised
Short Cognitive Examination (SCE) which could be
administered even to patients with moderately advanced
disease in their homes, and a comprehensive neuropsy-
chological examination for administration only to mildly
affected patients. Using both of these batteries we aimed
to detect a broad pattern of performance in the larger
patient group, which could then be investigated in more
detail in the smaller, less affected group.
Participants
Patients were recruited through the NHS National Prion
Clinic (NPC) at the National Hospital for Neurology &
Neurosurgery, UCLH NHS Foundation Trust, London,
U.K. Ethics approval for the study was granted by the
Eastern Multicentre Research Ethics Committee and
informed consent for participation was given either by
the patient or their next of kin. A total of 456 patients
with suspected or confirmed prion disease were recruited
to the National Prion Cohort Monitoring Study or MRC
PRION-1 trial from 2004 to May 2013. Of these, 81 partic-
ipants deemed to be symptomatic and able to complete the
SCE, were included in the study. Participants were
excluded if they were too impaired at the time of the initial
assessment to complete the SCE (139 cases); if they were at
risk of either genetic or iatrogenic disease but not symp-
tomatic (21 cases); or if they were eventually found to have
another neurological disorder (37 cases). Thirty patients
were well enough to travel and undergo comprehensive
neuropsychological assessment all of which were conducted
by D. C., usually in the Neuropsychology Department of
the National Hospital for Neurology and Neurosurgery.
Definitive diagnosis of prion disease was made either by
genetic testing in the case of inherited disease or by post-
mortem neuropathology. A matched control group of 36
healthy individuals recruited from amongst the patients’
families, to control for possible confounding factors such
as education and IQ, was also recruited to the study. This
included participants at risk of IPD but who on testing
were gene mutation negative. Thirty-three subjects from
the original control group underwent neuropsychological
testing in addition to the SCE.
Clinical testing
All participants underwent systematic neurological exami-
nation in addition to cognitive examination. The neuro-
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logical assessment included the NPC-devised MRC Prion
Disease Rating Scale which includes neurological, cogni-
tive, and functional components and provides a measure
of overall disease severity.20
Cognitive investigation of the patients comprised two
components:
1 The SCE included the Mini Mental State Examination
(MMSE) and a battery of tasks devised to target the
cognitive domains reported to be vulnerable in prion
disease.8,21 It included brief tests of the following (with
maximum number of items in brackets): recognition
memory (words [/12] and faces [/12]), attention (digit
span[/5]), parietal lobe function (spelling[/6], calculation
[/4], praxis[/10]), language (object naming[/12], reading
[/5]), executive function (letter fluency [number of words
in 60 sec]), perception (incomplete letter recognition[/3]),
and processing speed (letter cancellation [time taken]).
2 Neuropsychological examination which include a com-
prehensive battery of standardized tests: Current intellec-
tual functioning (WAIS-III [Wechsler 1997]; seven sub-
tests: vocabulary, similarities, digit span, arithmetic, pic-
ture completion, picture arrangement and block design);
premorbid optimal level of function (National Adult Read-
ing Test22); Visual and verbal recognition memory (Recog-
nition Memory Test23); visual (AMIPB complex figure24)
and verbal recall (Paired Associate Learning25) recall; Lan-
guage including nonword repetition,26 category (“Ani-
mal”) fluency; object naming (Graded Naming Test
(GNT)27) synonym matching; and sentence comprehen-
sion (Test for Reception of Grammar [TROG]28); Visual
perception and visuospatial function (Visual object and
space processing battery [VOSP] Object Decision, Cube
Analysis29; visuoconstruction24); limb praxis (meaning-
ful30) and meaningless31 gesture; spelling (Graded Diffi-
culty Spelling Test32); and calculation (Graded Difficulty
Calculation Test (GDCT)33); Executive function (Modified
Card Sorting Test34; Stroop Test35; Verbal fluency (FAS)36;
Trail Making Test [TMT] Part B37); and Information pro-
cessing speed (TMT Part A37).
The neuropsychological assessment was carried out at
the same time as the neurological and clinical investiga-
tions, or as close to that as possible.
Statistical analysis
We used analysis of variance (ANOVA) and independent
t-test or its nonparametric equivalent to compare
patients’ and controls’ scores on individual components
of the two batteries. Multiple comparisons were done
between different components, however, these were not
independent tests and therefore P values uncorrected for
multiple testing are presented. SCE scores were also sub-
jected to a principal components analysis (PCA) with
orthogonal varimax rotation to identify any clustering of
individual measures. The PCA also generated axes
(termed Axes 1, 2, etc. in rank order of declining propor-
tion of variance explained) which were used to investigate
possible correlation with demographic, clinical category,
genetic (PRNP mutation and polymorphic codon 129
genotype), and investigation variables (MRI brain signal
change in cortex, basal ganglia or thalamus, cerebrospinal
fluid (CSF) 14-3-3 protein and electroencephalography
[EEG]). To address the relative sensitivity of individual
tasks comprising each of the two batteries, we calculated
the proportion of patients whose performance was
impaired on each test. Missing data were treated with
a missing at random approach. Statistical analyses were
performed using the statistical package for the social
sciences V.11.5 (SPSS, IBM, New York).
MRI studies
Diagnostic MR brain images performed at multiple sites in
the U.K. were acquired and re-reported by H. H. and catego-
rized according to clinical normality/abnormality in cerebral
cortex (two areas involved and excluding areas known to
generate false-positive signal), thalamus, and basal ganglia.
For the subgroup of patients who attended National
Hospital for Neurology and Neurosurgery (NHNN) for
detailed neuropsychological assessment, 3 T MRI was also
acquired. Spatial processing for voxel based morphometry
(VBM) was performed for structural T1-weighted data
using SPM Version 8 software (SPM8, http://www.fil.io-
n.ucl.ac.uk/spm) as follows: (1) SPM8’s unified segmenta-
tion approach, which combines segmentation, bias
correction, and normalization to the MNI (Montreal
Neurological Institute) space into a single generative
model.38 The rigid component of the normalization trans-
formation was used to produce approximately aligned
images for the following step. (2) Generation of a cohort-
specific template for gray matter (GM) and white matter
(WM) segments using DARTEL.21 (3) Warping and re-
sampling of individual GM and WM segments to the
cohort-specific template. Local intensities were modulated
to account for volume changes associated with the nor-
malization. (4) An isotropic 6-mm full-width-at-half-
maximum (FWHM) Gaussian kernel was applied to the
gray and WM data sets. (5) An “objective” masking strat-
egy39 was employed to define the voxels for subsequent
statistical analysis on GM and WM segments separately.
For statistical analysis a group level random effect
model Analysis of Covariance (ANCOVA) consisting of
diagnostic grouping (controls, symptomatic patients)
with individual age and total intracranial volume
(GM + WM + CSF segments) as covariates, was per-
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formed. In the symptomatic patients, we also assessed the
correlation between PCA Axis 1 and Axis 2 scores with
GM and WM separately, with individual age and total
intracranial volume as covariates. For multiple compari-
son correction we used voxel-wise false discovery rate
(FDR) with P < 0.05. SPM-t maps were produced using a
P < 0.05 level of significance after multiple comparison
correction using FDR. After results were computed, they
were affine transformed to MNI, by affine registering the
Dartel template to the MNI space tissue prior probability
maps. Results are displayed overlaid on the average of the
warped T1 volumes, transformed to MNI space. To illus-
trate the actual change in GM fraction, a region of inter-
est (ROI) was chosen in the area of the largest cluster of
significant voxels. The ROI was manually drawn on the
average warped and smoothed T1 volumes by an experi-
enced neuroradiologist and verified on the averaged
smoothed data sets to ensure the smoothing did not cause
CSF contamination. The correlation between angular
gyrus GM fraction and neuropsychology was assessed
with the Spearman-rank correlation.
Results
Patient diagnosis
Demographic information and MMSE scores for the
patients who completed the SCE are reported in
Table 1(1). The diagnoses were: sCJD (n = 40/81, 49.5%);
IPD (n = 28/81, 34.5%); iatrogenic CJD (human pituitary
growth hormone) (n = 8/81, 10%); or vCJD (n = 5/81,
6%). The sCJD group included patients will all three
genotypes at polymorphic codon 129 of PRNP
(129MM = 7, 129MV = 20, 129VV = 12, 1 not tested).
The IPD group were made up of patients with nine dif-
ferent genetic mutations (P102L [n = 7], Y163X [n = 2],
5-OPRI [n = 4], 6-OPRI [n = 4], E200K [n = 4], E196K
[n = 1], D178N [n = 2], Q212P [n = 1], A117V [n = 3]).
Sixty-two patients subsequently died, 46 of whom had an
autopsy; the clinical diagnosis of prion disease was con-
firmed in all these. The control group was slightly youn-
ger on average than the patients (P = 0.020) and,
unsurprisingly, their MMSE scores were significantly
higher than those of the patients (P < 0.001).
Short cognitive examination
Disease severity, early signs, and symptoms and their rela-
tive distribution can be seen in Table 2(1). As expected,
there was a highly significant difference in mean score
between patients and healthy controls on all components
of the SCE (see Table S1). Comparison of the proportion
of patients with possible or probable impairment on each
test showed highly significant differences between tests
(ANOVA, P < 0.001, Fig. 1). These results raised the pos-
sibility that some cognitive domains may be more vulner-
able than others in this disease. Subgroups, including
disease category, age of onset, gender, PRNP codon 129,
and imaging variables, showed highly consistent test sen-
sitivities (see Table S3). Post hoc analyses also raised the
possibility of homogenous subgroups of tests (e.g., Letter
fluency, calculation, naming, letter cancelling, spelling,
praxis vs. all others, P = 0.05, Student–Newman–Keuls
method).
We went on to use PCA as a hypothesis free method to
identify key structures in the psychological data set. The
components can be conceptualized as a single variable
derived from combinations of test scores that account for
Table 1. Demographic information (1) with MMSE, for patients assessed on the SCE; and (2) with estimated IQ, for patients assessed on the neu-
ropsychological examination.
Patients Controls
N Age, mean (SD) MMSE, mean (SD) N Age, mean (SD) MMSE, mean (SD)
(1) SCE
Male 48 54.0 (14.0) 20.7 (6. 6) 18 51.0 (12.3) 29 (1.0)
Female 33 56.8 (11.6) 21.8 (5.0) 18 48.0 (13.6) 30 (0.70)
Total 81 55.4 (13.7) 21.2 (4.4) 36 49.3 (12.9) 29.5 (0.90)
Patients Controls
N Age, mean (SD) NART IQ, mean (SD) N Age, mean (SD) NART IQ, mean (SD)
(2) Neuropsychological examination
Male 16 49.7 (10.2) 105.1 (15.8) 17 50.0 (12.5) 104 (11.2)
Female 11 52.0 (12.4) 99.9 (9.5) 16 47.0 (14.5) 108 (15.9)
Total 30 50.6 (11.0) 103.0 (13.6) 33 49.0 (13.4) 106 (13.6)
SCE, short cognitive examination; NART, national adult reading test.
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 551
D. Caine et al. Prion Disease Neuropsychology
a maximal proportion of overall variance. The first com-
ponent (Axis 1) explained 42.1% of the variance in the
patient group. The second component (Axis 2) accounted
for just 15.4% of the variance (Table 3). Axis 1 was most
strongly correlated with the following tasks: spelling, cal-
culation, naming, digit span, reading, praxis and letter
fluency, very similar to the homogeneous subgroup sug-
gested by post hoc studies above. No significant correla-
tions were found between Axis 1 and diagnosis, mutation,
age, gender, or PRNP codon 129.
MRI analysis
From 30 patients attending for detailed neuropsychologi-
cal examination at NHNN, 23 patients had 3 T research
MRI. Estimated GM partial volume fraction significantly
correlated with Axis 1 (reduced GM content was associ-
ated with reduced Axis 1 score) in numerous frontal and
parietal regions including the superior parietal lobule, su-
pramarginal gyrus, inferior temporal gyrus, middle frontal
gyrus, inferior frontal gyrus and pars triangularis, more
on the left than on the right (Fig. 2). There were no sig-
nificant correlations between Axis 2 with either GM or
WM, nor between Axis 1 and WM. Angular gyrus GM
partial volume fraction correlated significantly with Axis 1
(Fig. 2C) with a Spearman rank correlation coefficient of
0.602 (P = 0.004).
Detailed neuropsychological examination
There was considerable heterogeneity in clinical presenta-
tion of the 30 patients undergoing detailed neuropsycho-
logical assessment (see Tables 1(2) and 2(2) for clinical
and demographic information). There was no age-differ-
ence between the patients and the healthy controls who
also underwent neuropsychological examination (t
[61] = 0.546, P = 0.590). In estimating IQ, based on the
national adult reading test (NART) reading test, three
patients with dyslexia were removed from the analysis.
Estimated IQ was very slightly higher amongst the healthy
controls (mean = 109.30, SD = 11.70) than patients
(mean = 103.0, SD = 13.6, P = 0.059).
Comparison of the difference between patients’ and
controls’ optimal full-scale IQ (FSIQ) as estimated on the
NART and current FSIQ as measured on the WAIS-III
showed a significant change for the patients (Wilcoxon
signed-rank test, P < 0.001) but not for the controls
(P = 0.062), confirming a marked decline in general intel-
lectual function in this disease. A significant difference
between patients and healthy controls was found on all
Table 2. Clinical features at the time of (1) SCE and (2) neuropsychological examination. The two most dominant clinical features are shown in bold.
Clinical feature
(1) SCE (n = 81)
N (%) patients affected
(2) Neuropsychological examination (n = 30)
N (%) patients affected
Cognitive complaint 72 (89) 22 (73)
Ataxia 63 (78) 16 (53)
Anxiety/depression 32 (39) 7 (23)
Speech difficulty 28 (35) 6 (20)
Personality change1 28 (35) 10 (33)
Apraxia 28 (35) 8 (27)
Myoclonus 26 (32) 6 (20)
Extra-pyramidal signs 19 (23) 5 (17)
Hallucinations/delusions 19 (23) 4 (13)
Pyramidal signs 17 (21) 1 (3)
Sensory Disturbance 17 (21) 1 (3)
Diarrhea 2 (2) 1 (3)
SCE, short cognitive examination.
1Aggressivity/irritability; withdrawal/loss of drive; emotional lability.
Letter Fluency 80%
Calculation 73%
Naming Objects 64%
Letter Cancelling 62%
Spelling 60%
Praxis 59%
Memory Verbal 56%
Memory Visual 53%
Digit Span 53%
Reading 23%
Fragmented Letters 21%
Figure 1. Percentage of patients impaired on each short cognitive
examination task.
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tasks, as was the case with the SCE (see Table S2). Thus,
here again the group analysis was not as helpful as inter-
rogation of individual patients’ scores in terms of eluci-
dating patterns of performance.
Based on our findings from analysis of the SCE we pre-
dicted that eight tasks would be most impaired on detailed
neuropsychological assessment (Stroop Test, TMT Part A,
TMT Part B, Praxis, GDCT, Animal fluency, FAS, and
GNT) compared with the 17 other tasks (see Table 4).
Considering only those impaired (>2 SD difference from
the mean of controls), 152/240 patient-tests were impaired
from those tests which were a priori expected to be most
abnormal; 207/510 patient-tests were impaired from the
remainder (P < 0.0001, Fisher’s exact test).
Table 4 shows for each patient whether performance
was impaired (>1 SD or >2 SD outside the mean for
healthy controls) on each test. The left-most group of col-
umns (gray headings) include the cognitive domains
reflected in Axis 1 and representing tests of executive
function, language, and parietal lobe function, and praxis.
The MRC Scale score can be seen alongside the patients’
MMSE score. The tests are arranged in each domain in
order of the decreasing percentage of patients liable to be
affected in that domain. Table 4 also demonstrates that
patients with more severe cognitive deficits as identified
on the MMSE were impaired in all domains, and some-
times on all or almost all the tasks in each domain. What
is of interest here is domains in which the more mildly
affected patients were also shown to have deficits, thus
offering the possibility of eliciting a more subtle pattern
of cognitive decline.
All of the patients were impaired on at least one execu-
tive task, with a majority (23/30; 77%) performing below
healthy controls on three of the four tests of executive
function. A significant proportion was also impaired on
tests of language (24/30; 80%). This included not only
category fluency (24/30; 80%) and object naming (GNT:
20/30; 67%), but also sentence comprehension (TROG:
21/30; 70%). In contrast only 50% (15/30) had difficulty
with a nonspoken test of semantic knowledge (Concrete
Synonym Matching), and only 47% (14/30) on each of
two tests of repetition. In terms of parietal function both
calculation GDC: 23/30; 77%) and praxis (21/30; 70%)
were impaired even in more mildly affected patients.
While performance on the other parietal tests individually
were less liable to be affected as many as 83% (25/30) of
patients experienced parietal lobe dysfunction of one kind
or another. Thus, confirming the outcome of the PCA for
the SCE, the most prominent cognitive symptom, even in
Table 3. Principal components analysis axis loadings. Bold tests are
the strongest correlates of each axis
1 2
Spelling 0.828 0.226
Calculation 0.792 0.194
Naming 0.761 0.243
Digit span 0.758 0.089
Reading 0.693 0.157
Praxis 0.594 0.376
Letter fluency 0.552 0.441
Fragmented letters 0.409 0.367
MRC scale 0.010 0.795
Memory – visual 0.310 0.785
Letter cancel 0.054 0.773
Memory – verbal 0.226 0.693
Figure 2. Correlation between gray matter volume reduction and
decline in Axis 1 score in symptomatic patients. (A) Axial and (B)
coronal SPM-t maps showing in red–yellow voxels demonstrating
statistically significant correlation between GM volume reduction and
decline in 1st SCE-PCA component (Axis 1) score in symptomatic
patients (n = 23). Results are shown using false discovery rate
q < 0.05 to control for multiple comparisons, and are overlaid on the
average of all the anatomical data set registered to the group-specific
template. The colorbar range for t-values is 2.5–5. (C) Scatter plot
showing correlation of GM partial volume fraction with Axis 1 over an
ROI manually drawn in the left angular gyrus: Spearman-rank
correlation coefficient = 0.602, P = 0.004. SCE, short cognitive
examination; PCA, principal components analysis; GM, gray matter;
ROI, region of interest.
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the context of mild disease, was executive function with
performance also poor on tests of both language (27/30;
90%) and, to a slightly lesser extent, parietal function
(25/30; 83%).
Turning to the other cognitive domains, of the memory
tasks, nonverbal recall was the most liable to be affected.
Of the patients who performed poorly at figure recall,
however, 75% (18/24) also scored poorly on the copy con-
dition of the task, with which scores on the memory task
were strongly correlated (r = 0.563, P < 0.001). This likely
reflects the significant visuospatial demand of this task.
Fewer patients were impaired on the other memory tasks
(13/30; 43%–19/30; 63%), consistent with the fact that
memory did not load significantly on the first component
of the PCA. A large proportion of patients (25/30; 83%)
were impaired on a test of psychomotor processing speed
(TMTA), a task with strong visuoperceptual and motor
demands. Fewer were affected on two less perceptually
demanding tests of speed and attention (Reading time on
the Stroop Test: 15/30; 50%; Forward Digits: 14/30; 47%).
In summary, consistent with the findings on the SCE, the
individual neuropsychology patient data revealed a profile
comprising prominent executive, language and parietal
deficits with memory, speed and attention relatively
spared. This was most evident in the ten most mildly
affected patients (Table 4, cases 1–10, MMSE ≥29).
Discussion
We have studied a large group of mildly affected prion dis-
ease patients by comprehensive, systematic cognitive inves-
tigation, and correlated these measures with clinical and
molecular investigation. Consistent with the view that
prion disease gives rise to pervasive cognitive decline, most
patients were impaired in all or most cognitive domains.
Nevertheless, principle component analysis revealed an axis
comprising tests of frontal executive function, language
and parietal functions, which accounted for almost half the
variance in the sample. This axis also correlated strongly
with GM atrophy in frontal and parietal areas detected on
MRI. When patients were ranked by MMSE score, the
implicated tests were found to be impaired in incipient dis-
ease. Taken together, these findings indicate that a coher-
ent constellation of cognitive variables associated with
fronto-parietal function can be considered the leading cog-
nitive features in prion disease, irrespective of etiology.
Executive dysfunction was shown to be a leading
cognitive symptom, with all patients impaired in this
domain. Executive deficits are often a feature of dementia
syndromes40 but they are usually not the leading sign,
although PSP may be an exception in this regard.41
Executive deficits were accompanied by personality
change – irritability, aggressiveness, emotional lability – in
about half of patients undergoing either the SCE or full
neuropsychological assessment. There is little suggestion
in prion disease, however, of the disorder of social cogni-
tion with disinhibition seen in behavioral variant fronto-
temporal dementia (bvFTD).42
Even mildly affected patients were impaired on some
language tasks: letter fluency, animal fluency, sentence
comprehension, and object naming. Fewer were impaired
on tests of repetition or semantic knowledge. Unlike the
logopaenia associated with repetition deficits seen in Alz-
heimer’s disease,43 prion patients have reduced output
and poor sentence comprehension without repetition def-
icits, suggesting an executive rather than a phonological
underpinning to the language disorder, the precise nature
of which is yet to be elucidated.
Although memory complaints are common, memory
contributed only to the second axis of the PCA. Just half
the sample performed poorly on all or even most of the
memory tasks. Many patients were impaired on the adult
memory and information processing battery (AMIPB) test
of delayed figure recall although, as suggested earlier, this
was partly due to impaired visuospatial function, evident
in a poor figure copy. Clinically, prion patients are not
repetitive in conversation, do not characteristically fail to
recognize clinicians and others, and do not seem bewil-
dered in their forgetfulness in the way that patients with
Alzheimer’s disease (AD) do. These findings confirm the
impression that, unlike typical AD or even bvFTD,44 an
amnesic syndrome per se is not a particularly prominent
feature. This may reflect the distribution of pathological
changes, implicating the thalamus and basal ganglia in
prion disease rather than the frontal, temporal, and pos-
terior cortical regions known to be differentially affected
in AD and FTD.45
Although the first component of the PCA included
digit span, calculation, and reading, detailed neuropsycho-
logical assessment of these functions showed only calcula-
tion to be vulnerable in the majority of patients. On the
other hand taking all parietal tasks into account, many
patients were impaired in this domain (83%). Apraxia
was present in more than two-thirds of cases. Thus,
although there is evidence of significant parietal compro-
mise bilaterally, the specific symptomatology is somewhat
variable from case to case.
The cognitive signs in mild prion disease thus comprise
executive deficits, a largely expressive language disorder,
and a constellation of parietal signs including visuospatial
impairment and apraxia. Memory is less markedly
affected as are semantic knowledge, processing speed and
attention. The cognitive deficits arise in the context of a
movement disorder in the form of ataxia with other neu-
rological signs including myoclonus and apraxia affecting
a smaller proportion of patients. From the point of view
ª 2015 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 555
D. Caine et al. Prion Disease Neuropsychology
of differential diagnosis, prion disease thus resembles
movement disorders with associated dementia syndromes
including corticobasal degeneration (CBD), PSP, Amyo-
trophic lateral sclerosis (ALS), and perhaps Lewy body
disease. A review of the CBD literature46 yielded a very
similar result to that reported here: heterogeneity of pre-
sentation but with characteristic features including limb
apraxia, constructional and visuospatial difficulties, acal-
culia, frontal dysfunction, and a nonfluent aphasia. Epi-
sodic memory was variable, but when present impairment
tended to be milder than in Alzheimer’s disease. Semantic
memory is relatively preserved but a nonfluent speech
disturbance is common, and may be the presenting fea-
ture.46 A similar neuropsychological profile has also been
reported in PSP47 without the prominent language disor-
der and with a different constellation of neurological
signs. Language and executive deficits have been found to
be the most prominent cognitive features in ALS, together
with changes in behavior and social cognition. Parietal
signs are less frequent and the neurological concomitants
are also very different from those seen in prion dis-
ease.48,49 Dementia with Lewy bodies also falls within the
constellation with a characteristic profile of deficits in vi-
suospatial ability and frontal executive function accompa-
nied by mild-to-moderate Parkinsonism.50 Language
disturbance is not a prominent feature. Prion disease is
thus most similar to CBD but with both a language disor-
der and motor features that are distinctly different from
that condition in the majority of patients.
The results of this study give strong indications for an
appropriate test battery for early diagnosis of prion dis-
ease. In our view, this should comprise tests of: (1) execu-
tive function including response inhibition (Stroop) and
generativity (verbal fluency); (2) tests of parietal function
including higher order visuospatial function (complex fig-
ure copy), calculation and praxis; (3) tests of language
including language production (category fluency, non-
word repetition) and sentence comprehension; (4) tests of
speed of information processing. Tests of memory, visual
processing, reading and attention should also be included
to avoid false positive findings.
In summary, this is the only large study of the neuro-
psychology of prion disease ever undertaken. Overall, the
results confirm that all patients ultimately develop a glo-
bal cognitive impairment. However, our data clearly show
that frontal and parietal functions are particularly vulner-
able in the context of mild disease, even allowing for dif-
ferences in the overall pattern of symptomatology,
including neurological and psychiatric features, in some
forms of the disease. This neuropsychological profile
taken together with the characteristic neurological features
of the disease constitutes a signature that should lead to
more straightforward and rapid differential diagnosis of
incipient cases in a clinical setting. Given the prospect of
further clinical trials for prion disease, we have recom-
mended that functionally orientated scales should be used
in rapidly progressive patients.51 Asymptomatic at-risk
individuals and early symptomatic patients, such as those
studied in this paper, represent an alternative and attrac-
tive group to target with an experimental therapy, assum-
ing an adequate safety profile, prior to extensive neuronal
damage. Future work building on this study will be direc-
ted toward operationalization of a neuropsychological test
battery and natural history database to enable timing of
disease onset and document cognitive progression in these
patient groups. This may be facilitated by further charac-
terization and differentiation of the language disorder in
prion disease, in comparison with those found in fronto-
temporal lobar degeneration and Alzheimer’s disease.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Table S1. Comparison of patients’ and controls’ mean
scores on all components of the SCE using the Mann–
Whitney U-Test.
Table S2. Comparison of patients’ and controls’ mean
scores on all components of the Neuropsychological
Examination using the Mann–Whitney U-Test.
Table S3. Consistent impairments in prion disease sub-
groups. Ranking of proportion of subjects impaired or
possibly impaired (>1 SD below mean, or imperfect score
if all controls scored perfectly) from most to least propor-
tion impaired. The proportion impaired in each neuro-
psychological test was remarkably consistent in the
known subgroups of disease, early age of onset, gender,
PRNP codon 129 genotype and imaging findings. Note
that too few subjects had normal CSF or EEG examina-
tions to allow for meaningful comparisons of these diag-
nostic tests.
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